ArticleThe oncologist2025

Anti-PD-1 antibody with or without capecitabine as maintenance therapy after first-line therapy of recurrent or metastatic nasopharyngeal carcinoma.

Yi-Fu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.